Enzymatica’s CEO on the road ahead for ColdZyme

One year has passed since the clinical results for ColdZyme were published in the scientific journal The Journal of Physiology. The study showed that ColdZyme can reduce rhinovirus levels by 94 percent and shorten the duration of the common cold by up to four days when used at the first signs of symptoms. 

Since publication, the results have played an important role in Enzymatica’s continued work and in the company’s dialogue with international partners and distributors. The clinical evidence provides an important foundation for the company’s ongoing expansion in the global common cold market.

In a new interview with BioStock, Enzymatica’s CEO Sana Alajmovic discusses how the study has influenced the company’s strategic work and outlines the next steps in the development of ColdZyme.

Read the full interview at Biostock: One year after the clinical results – Enzymatica's CEO on the road ahead for ColdZyme